SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) and heart failure (HF) are significant global health issues.
• T2DM and HF are mutually exacerbating conditions, leading to poorer prognoses when co-occurring.
• Historically, T2DM and HF have been treated as independent pathologies.

Purpose of the Study:

• To explore the intricate relationship between T2DM and HF.
• To discuss the concept of diabetic cardiomyopathy.
• To summarize the impact of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on HF hospitalizations and their mechanisms.

Main Methods:

• Review of recent cardiovascular outcome trials.
• Analysis of pathophysiological mechanisms linking T2DM and HF.
• Synthesis of data on SGLT-2i efficacy in managing co-morbid T2DM and HF.

Main Results:

• SGLT-2 inhibitors demonstrate efficacy in managing both T2DM and HF.
• Evidence suggests SGLT-2i reduce HF hospitalizations in patients with T2DM.
• Proposed pathophysiological mechanisms underlying these effects are explored.

Conclusions:

• The treatment paradigm for T2DM and HF is evolving with the advent of SGLT-2i.
• SGLT-2i represent a significant therapeutic advancement for patients with both conditions.
• Further research into the mechanisms of SGLT-2i in diabetic cardiomyopathy is warranted.